AustralieFrV1, PascalFrancis, Corpus, bibRecord, 000B60

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Identifieur interne : 000B60 ( PascalFrancis/Corpus ); précédent : 000B59; suivant : 000B61

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Auteurs : Charles J. Ryan ; Mark Rosenthal ; Siobhan Ng ; Joshi Alumkal ; Joel Picus ; Gwenaëlle Gravis ; Karim Fizazi ; Frédéric Forget ; Jean-Pascal Machiels ; Sandy Srinivas ; MIN ZHU ; RUI TANG ; Kellys. Oliner ; YIZHOUJIANG ; Elwyn Loh ; Sarita Dubey ; Winald R. Gerritsen

Source :

Clinical cancer research [ 1078-0432 ] ; 2013.

RBID : Pascal:13-0119238

Descripteurs français

Pascal (Inist)
- Cible, Ciblage, Protooncogène, Gène onc cellulaire, Inhibiteur, Inhibition, Castration, Résistance, Cancer de la prostate, Randomisation, Homme, Essai clinique phase II, Traitement, Marqueur biologique, Analyse, Mitoxantrone, Prednisone, Anticancéreux, Rilotumumab.

English descriptors

KwdEn :
- Analysis, Antineoplastic agent, Biological marker, C-Onc gene, Castration, Human, Inhibition, Inhibitor, Mitoxantrone, Phase II trial, Prednisone, Prostate cancer, Protooncogene, Randomization, Resistance, Rilotumumab, Target, Targeting, Treatment.

Abstract

Purpose: To evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (IIGF)/scatter factor, combined with mitoxantrone and prednisone (MP) in patients with castration-resistant prostate cancer (CRPC). Experimental Design: This double-blinded phase II study randomized (1:1:1) patients with progressive, taxane-refractory CRPC to receive MP (12 mg/m² i.v. day 1, 5 mg twice a day orally days 1-21, respectively) plus 15 mg/kg rilotumumab, 7.5 mg/kg rilotumumab, or placebo (i.v. day 1) every 3 weeks. The primary endpoint was overall survival (OS). Results: One hundred and forty-four patients were randomized. Median OS was 12.2 versus 11.1 months [HR, 1.10; 80% confidence interval (CI), 0.82-1.48] in the combined rilotumumab versus control arms. Median progression-free survival was 3.0 versus 2.9 months (HR, 1.02; 80% CI, 0.79-1.31). Treatment appeared well tolerated with peripheral edema (24% vs. 8%) being more common with rilotumumab. A trend toward unfavorable OS was observed in patients with high tumor MET expression regardless of treatment. Soluble MET levels increased in all treatment arms. Total HGF levels increased in the rilotumumab arms. Rilotumumab showed linear pharmacokinetics when co-administered with MP. Conclusions: Rilotumumab plus MP had manageable toxicities and showed no efficacy improvements in this estimation study. High tumor MET expression may identify patients with CRPC with poorer prognosis.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1078-0432`
A02	`01`			`@0 CCREF4`
A03		`1`		`@0 Clin. cancer res.`
A05				`@2 19`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone`
A11	`01`	`1`		`@1 RYAN (Charles J.)`
A11	`02`	`1`		`@1 ROSENTHAL (Mark)`
A11	`03`	`1`		`@1 NG (Siobhan)`
A11	`04`	`1`		`@1 ALUMKAL (Joshi)`
A11	`05`	`1`		`@1 PICUS (Joel)`
A11	`06`	`1`		`@1 GRAVIS (Gwenaëlle)`
A11	`07`	`1`		`@1 FIZAZI (Karim)`
A11	`08`	`1`		`@1 FORGET (Frédéric)`
A11	`09`	`1`		`@1 MACHIELS (Jean-Pascal)`
A11	`10`	`1`		`@1 SRINIVAS (Sandy)`
A11	`11`	`1`		`@1 MIN ZHU`
A11	`12`	`1`		`@1 RUI TANG`
A11	`13`	`1`		`@1 OLINER (KellyS.)`
A11	`14`	`1`		`@1 YIZHOUJIANG`
A11	`15`	`1`		`@1 LOH (Elwyn)`
A11	`16`	`1`		`@1 DUBEY (Sarita)`
A11	`17`	`1`		`@1 GERRITSEN (Winald R.)`
A14	`01`			`@1 University of California San Francisco Helen Diller Family Comprehensive Cancer Center @2 San Francisco @3 USA @Z 1 aut. @Z 11 aut.`
A14	`02`			`@1 The Royal Melbourne Hospital @2 Parkville @3 AUS @Z 2 aut.`
A14	`03`			`@1 St. John of God Health Care @2 Subiaco @3 AUS @Z 3 aut.`
A14	`04`			`@1 Oregon Health & Science University Knight Cancer Institute @2 Portland @3 USA @Z 4 aut.`
A14	`05`			`@1 Washington University School of Medicine Site-man Cancer Center @2 St. Louis @3 USA @Z 5 aut.`
A14	`06`			`@1 Institut Paoli Calmettes @2 Marseille @3 FRA @Z 6 aut.`
A14	`07`			`@1 Institut Gustave Roussy, University of Paris Sud @2 Villejuif @3 FRA @Z 7 aut.`
A14	`08`			`@1 Centre Hospitalier de l'Ardenne @2 Libramont @3 BEL @Z 8 aut.`
A14	`09`			`@1 Université Catholique de Louvain, Cliniques Universitaires Saint-Luc @2 Bruxelles @3 BEL @Z 9 aut.`
A14	`10`			`@1 Stanford University @2 Palo Alto @3 USA @Z 10 aut.`
A14	`11`			`@1 Amgen Inc. @2 Thousand Oaks @3 USA @Z 12 aut. @Z 13 aut. @Z 14 aut.`
A14	`12`			`@1 Amgen Inc. @2 South San Francisco @3 USA @Z 15 aut. @Z 16 aut.`
A14	`13`			`@1 VU Medisch Centrum, Amsterdam/Radboud University Medical Center @2 Nijmegen @3 NLD @Z 17 aut.`
A20				`@1 215-224`
A21				`@1 2013`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 26073 @5 354000502414060230`
A44				`@0 0000 @1 © 2013 INIST-CNRS. All rights reserved.`
A45				`@0 27 ref.`
A47	`01`	`1`		`@0 13-0119238`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Clinical cancer research`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Purpose: To evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (IIGF)/scatter factor, combined with mitoxantrone and prednisone (MP) in patients with castration-resistant prostate cancer (CRPC). Experimental Design: This double-blinded phase II study randomized (1:1:1) patients with progressive, taxane-refractory CRPC to receive MP (12 mg/m² i.v. day 1, 5 mg twice a day orally days 1-21, respectively) plus 15 mg/kg rilotumumab, 7.5 mg/kg rilotumumab, or placebo (i.v. day 1) every 3 weeks. The primary endpoint was overall survival (OS). Results: One hundred and forty-four patients were randomized. Median OS was 12.2 versus 11.1 months [HR, 1.10; 80% confidence interval (CI), 0.82-1.48] in the combined rilotumumab versus control arms. Median progression-free survival was 3.0 versus 2.9 months (HR, 1.02; 80% CI, 0.79-1.31). Treatment appeared well tolerated with peripheral edema (24% vs. 8%) being more common with rilotumumab. A trend toward unfavorable OS was observed in patients with high tumor MET expression regardless of treatment. Soluble MET levels increased in all treatment arms. Total HGF levels increased in the rilotumumab arms. Rilotumumab showed linear pharmacokinetics when co-administered with MP. Conclusions: Rilotumumab plus MP had manageable toxicities and showed no efficacy improvements in this estimation study. High tumor MET expression may identify patients with CRPC with poorer prognosis.
C02	`01`	`X`		`@0 002B02R`
C02	`02`	`X`		`@0 002B14D02`
C02	`03`	`X`		`@0 002B20B02`
C03	`01`	`X`	`FRE`	`@0 Cible @5 01`
C03	`01`	`X`	`ENG`	`@0 Target @5 01`
C03	`01`	`X`	`SPA`	`@0 Blanco @5 01`
C03	`02`	`X`	`FRE`	`@0 Ciblage @5 02`
C03	`02`	`X`	`ENG`	`@0 Targeting @5 02`
C03	`02`	`X`	`SPA`	`@0 Blancado @5 02`
C03	`03`	`X`	`FRE`	`@0 Protooncogène @5 03`
C03	`03`	`X`	`ENG`	`@0 Protooncogene @5 03`
C03	`03`	`X`	`SPA`	`@0 Protooncogen @5 03`
C03	`04`	`X`	`FRE`	`@0 Gène onc cellulaire @5 04`
C03	`04`	`X`	`ENG`	`@0 C-Onc gene @5 04`
C03	`04`	`X`	`SPA`	`@0 Gen onc celular @5 04`
C03	`05`	`X`	`FRE`	`@0 Inhibiteur @5 05`
C03	`05`	`X`	`ENG`	`@0 Inhibitor @5 05`
C03	`05`	`X`	`SPA`	`@0 Inhibidor @5 05`
C03	`06`	`X`	`FRE`	`@0 Inhibition @5 06`
C03	`06`	`X`	`ENG`	`@0 Inhibition @5 06`
C03	`06`	`X`	`SPA`	`@0 Inhibición @5 06`
C03	`07`	`X`	`FRE`	`@0 Castration @5 07`
C03	`07`	`X`	`ENG`	`@0 Castration @5 07`
C03	`07`	`X`	`SPA`	`@0 Castración @5 07`
C03	`08`	`X`	`FRE`	`@0 Résistance @5 08`
C03	`08`	`X`	`ENG`	`@0 Resistance @5 08`
C03	`08`	`X`	`SPA`	`@0 Resistencia @5 08`
C03	`09`	`X`	`FRE`	`@0 Cancer de la prostate @2 NM @5 09`
C03	`09`	`X`	`ENG`	`@0 Prostate cancer @2 NM @5 09`
C03	`09`	`X`	`SPA`	`@0 Cáncer de la próstata @2 NM @5 09`
C03	`10`	`X`	`FRE`	`@0 Randomisation @5 10`
C03	`10`	`X`	`ENG`	`@0 Randomization @5 10`
C03	`10`	`X`	`SPA`	`@0 Aleatorización @5 10`
C03	`11`	`X`	`FRE`	`@0 Homme @5 11`
C03	`11`	`X`	`ENG`	`@0 Human @5 11`
C03	`11`	`X`	`SPA`	`@0 Hombre @5 11`
C03	`12`	`X`	`FRE`	`@0 Essai clinique phase II @5 12`
C03	`12`	`X`	`ENG`	`@0 Phase II trial @5 12`
C03	`12`	`X`	`SPA`	`@0 Ensayo clínico fase II @5 12`
C03	`13`	`X`	`FRE`	`@0 Traitement @5 13`
C03	`13`	`X`	`ENG`	`@0 Treatment @5 13`
C03	`13`	`X`	`SPA`	`@0 Tratamiento @5 13`
C03	`14`	`X`	`FRE`	`@0 Marqueur biologique @5 14`
C03	`14`	`X`	`ENG`	`@0 Biological marker @5 14`
C03	`14`	`X`	`SPA`	`@0 Marcador biológico @5 14`
C03	`15`	`X`	`FRE`	`@0 Analyse @5 15`
C03	`15`	`X`	`ENG`	`@0 Analysis @5 15`
C03	`15`	`X`	`SPA`	`@0 Análisis @5 15`
C03	`16`	`X`	`FRE`	`@0 Mitoxantrone @2 NK @2 FR @5 16`
C03	`16`	`X`	`ENG`	`@0 Mitoxantrone @2 NK @2 FR @5 16`
C03	`16`	`X`	`SPA`	`@0 Mitoxantrona @2 NK @2 FR @5 16`
C03	`17`	`X`	`FRE`	`@0 Prednisone @2 NK @2 FR @5 17`
C03	`17`	`X`	`ENG`	`@0 Prednisone @2 NK @2 FR @5 17`
C03	`17`	`X`	`SPA`	`@0 Prednisona @2 NK @2 FR @5 17`
C03	`18`	`X`	`FRE`	`@0 Anticancéreux @5 23`
C03	`18`	`X`	`ENG`	`@0 Antineoplastic agent @5 23`
C03	`18`	`X`	`SPA`	`@0 Anticanceroso @5 23`
C03	`19`	`X`	`FRE`	`@0 Rilotumumab @4 CD @5 96`
C03	`19`	`X`	`ENG`	`@0 Rilotumumab @4 CD @5 96`
C03	`19`	`X`	`SPA`	`@0 Rilotumumab @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'appareil génital mâle @5 37`
C07	`01`	`X`	`ENG`	`@0 Male genital diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato genital macho patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'appareil urinaire @5 38`
C07	`02`	`X`	`ENG`	`@0 Urinary system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Aparato urinario patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Tumeur maligne @2 NM @5 39`
C07	`03`	`X`	`ENG`	`@0 Malignant tumor @2 NM @5 39`
C07	`03`	`X`	`SPA`	`@0 Tumor maligno @2 NM @5 39`
C07	`04`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`04`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`04`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`05`	`X`	`FRE`	`@0 Pathologie de la prostate @5 40`
C07	`05`	`X`	`ENG`	`@0 Prostate disease @5 40`
C07	`05`	`X`	`SPA`	`@0 Prostata patología @5 40`
C07	`06`	`X`	`FRE`	`@0 Anticorps monoclonal @5 41`
C07	`06`	`X`	`ENG`	`@0 Monoclonal antibody @5 41`
C07	`06`	`X`	`SPA`	`@0 Anticuerpo monoclonal @5 41`
C07	`07`	`X`	`FRE`	`@0 Agent alkylant @5 42`
C07	`07`	`X`	`ENG`	`@0 Alkylating agent @5 42`
C07	`07`	`X`	`SPA`	`@0 Agente alquilante @5 42`
C07	`08`	`X`	`FRE`	`@0 Dérivé de l'anthraquinone @5 43`
C07	`08`	`X`	`ENG`	`@0 Anthraquinone derivatives @5 43`
C07	`08`	`X`	`SPA`	`@0 Antraquinona derivado @5 43`
C07	`09`	`X`	`FRE`	`@0 Antimétabolite @5 44`
C07	`09`	`X`	`ENG`	`@0 Antimetabolic @5 44`
C07	`09`	`X`	`SPA`	`@0 Antimetabólito @5 44`
C07	`10`	`X`	`FRE`	`@0 Corticostéroïde @5 45`
C07	`10`	`X`	`ENG`	`@0 Corticosteroid @5 45`
C07	`10`	`X`	`SPA`	`@0 Corticoesteroide @5 45`
C07	`11`	`X`	`FRE`	`@0 Hormone surrénalienne @5 46`
C07	`11`	`X`	`ENG`	`@0 Adrenal hormone @5 46`
C07	`11`	`X`	`SPA`	`@0 Hormona suprarrenal @5 46`
N21				`@1 091`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 13-0119238 INIST
ET :	Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone
AU :	RYAN (Charles J.); ROSENTHAL (Mark); NG (Siobhan); ALUMKAL (Joshi); PICUS (Joel); GRAVIS (Gwenaëlle); FIZAZI (Karim); FORGET (Frédéric); MACHIELS (Jean-Pascal); SRINIVAS (Sandy); MIN ZHU; RUI TANG; OLINER (KellyS.); YIZHOUJIANG; LOH (Elwyn); DUBEY (Sarita); GERRITSEN (Winald R.)
AF :	University of California San Francisco Helen Diller Family Comprehensive Cancer Center/San Francisco/Etats-Unis (1 aut., 11 aut.); The Royal Melbourne Hospital/Parkville/Australie (2 aut.); St. John of God Health Care/Subiaco/Australie (3 aut.); Oregon Health & Science University Knight Cancer Institute/Portland/Etats-Unis (4 aut.); Washington University School of Medicine Site-man Cancer Center/St. Louis/Etats-Unis (5 aut.); Institut Paoli Calmettes/Marseille/France (6 aut.); Institut Gustave Roussy, University of Paris Sud/Villejuif/France (7 aut.); Centre Hospitalier de l'Ardenne/Libramont/Belgique (8 aut.); Université Catholique de Louvain, Cliniques Universitaires Saint-Luc/Bruxelles/Belgique (9 aut.); Stanford University/Palo Alto/Etats-Unis (10 aut.); Amgen Inc./Thousand Oaks/Etats-Unis (12 aut., 13 aut., 14 aut.); Amgen Inc./South San Francisco/Etats-Unis (15 aut., 16 aut.); VU Medisch Centrum, Amsterdam/Radboud University Medical Center/Nijmegen/Pays-Bas (17 aut.)
DT :	Publication en série; Niveau analytique
SO :	Clinical cancer research; ISSN 1078-0432; Coden CCREF4; Etats-Unis; Da. 2013; Vol. 19; No. 1; Pp. 215-224; Bibl. 27 ref.
LA :	Anglais
EA :	Purpose: To evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (IIGF)/scatter factor, combined with mitoxantrone and prednisone (MP) in patients with castration-resistant prostate cancer (CRPC). Experimental Design: This double-blinded phase II study randomized (1:1:1) patients with progressive, taxane-refractory CRPC to receive MP (12 mg/m² i.v. day 1, 5 mg twice a day orally days 1-21, respectively) plus 15 mg/kg rilotumumab, 7.5 mg/kg rilotumumab, or placebo (i.v. day 1) every 3 weeks. The primary endpoint was overall survival (OS). Results: One hundred and forty-four patients were randomized. Median OS was 12.2 versus 11.1 months [HR, 1.10; 80% confidence interval (CI), 0.82-1.48] in the combined rilotumumab versus control arms. Median progression-free survival was 3.0 versus 2.9 months (HR, 1.02; 80% CI, 0.79-1.31). Treatment appeared well tolerated with peripheral edema (24% vs. 8%) being more common with rilotumumab. A trend toward unfavorable OS was observed in patients with high tumor MET expression regardless of treatment. Soluble MET levels increased in all treatment arms. Total HGF levels increased in the rilotumumab arms. Rilotumumab showed linear pharmacokinetics when co-administered with MP. Conclusions: Rilotumumab plus MP had manageable toxicities and showed no efficacy improvements in this estimation study. High tumor MET expression may identify patients with CRPC with poorer prognosis.
CC :	002B02R; 002B14D02; 002B20B02
FD :	Cible; Ciblage; Protooncogène; Gène onc cellulaire; Inhibiteur; Inhibition; Castration; Résistance; Cancer de la prostate; Randomisation; Homme; Essai clinique phase II; Traitement; Marqueur biologique; Analyse; Mitoxantrone; Prednisone; Anticancéreux; Rilotumumab
FG :	Pathologie de l'appareil génital mâle; Pathologie de l'appareil urinaire; Tumeur maligne; Cancer; Pathologie de la prostate; Anticorps monoclonal; Agent alkylant; Dérivé de l'anthraquinone; Antimétabolite; Corticostéroïde; Hormone surrénalienne
ED :	Target; Targeting; Protooncogene; C-Onc gene; Inhibitor; Inhibition; Castration; Resistance; Prostate cancer; Randomization; Human; Phase II trial; Treatment; Biological marker; Analysis; Mitoxantrone; Prednisone; Antineoplastic agent; Rilotumumab
EG :	Male genital diseases; Urinary system disease; Malignant tumor; Cancer; Prostate disease; Monoclonal antibody; Alkylating agent; Anthraquinone derivatives; Antimetabolic; Corticosteroid; Adrenal hormone
SD :	Blanco; Blancado; Protooncogen; Gen onc celular; Inhibidor; Inhibición; Castración; Resistencia; Cáncer de la próstata; Aleatorización; Hombre; Ensayo clínico fase II; Tratamiento; Marcador biológico; Análisis; Mitoxantrona; Prednisona; Anticanceroso; Rilotumumab
LO :	INIST-26073.354000502414060230
ID :	13-0119238

Links to Exploration step

Pascal:13-0119238

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone</title>
<author><name sortKey="Ryan, Charles J" sort="Ryan, Charles J" uniqKey="Ryan C" first="Charles J." last="Ryan">Charles J. Ryan</name>
<affiliation><inist:fA14 i1="01"><s1>University of California San Francisco Helen Diller Family Comprehensive Cancer Center</s1>
<s2>San Francisco</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rosenthal, Mark" sort="Rosenthal, Mark" uniqKey="Rosenthal M" first="Mark" last="Rosenthal">Mark Rosenthal</name>
<affiliation><inist:fA14 i1="02"><s1>The Royal Melbourne Hospital</s1>
<s2>Parkville</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ng, Siobhan" sort="Ng, Siobhan" uniqKey="Ng S" first="Siobhan" last="Ng">Siobhan Ng</name>
<affiliation><inist:fA14 i1="03"><s1>St. John of God Health Care</s1>
<s2>Subiaco</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alumkal, Joshi" sort="Alumkal, Joshi" uniqKey="Alumkal J" first="Joshi" last="Alumkal">Joshi Alumkal</name>
<affiliation><inist:fA14 i1="04"><s1>Oregon Health & Science University Knight Cancer Institute</s1>
<s2>Portland</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Picus, Joel" sort="Picus, Joel" uniqKey="Picus J" first="Joel" last="Picus">Joel Picus</name>
<affiliation><inist:fA14 i1="05"><s1>Washington University School of Medicine Site-man Cancer Center</s1>
<s2>St. Louis</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gravis, Gwenaelle" sort="Gravis, Gwenaelle" uniqKey="Gravis G" first="Gwenaëlle" last="Gravis">Gwenaëlle Gravis</name>
<affiliation><inist:fA14 i1="06"><s1>Institut Paoli Calmettes</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name>
<affiliation><inist:fA14 i1="07"><s1>Institut Gustave Roussy, University of Paris Sud</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Forget, Frederic" sort="Forget, Frederic" uniqKey="Forget F" first="Frédéric" last="Forget">Frédéric Forget</name>
<affiliation><inist:fA14 i1="08"><s1>Centre Hospitalier de l'Ardenne</s1>
<s2>Libramont</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Machiels, Jean Pascal" sort="Machiels, Jean Pascal" uniqKey="Machiels J" first="Jean-Pascal" last="Machiels">Jean-Pascal Machiels</name>
<affiliation><inist:fA14 i1="09"><s1>Université Catholique de Louvain, Cliniques Universitaires Saint-Luc</s1>
<s2>Bruxelles</s2>
<s3>BEL</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Srinivas, Sandy" sort="Srinivas, Sandy" uniqKey="Srinivas S" first="Sandy" last="Srinivas">Sandy Srinivas</name>
<affiliation><inist:fA14 i1="10"><s1>Stanford University</s1>
<s2>Palo Alto</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Min Zhu" sort="Min Zhu" uniqKey="Min Zhu" last="Min Zhu">MIN ZHU</name>
<affiliation><inist:fA14 i1="01"><s1>University of California San Francisco Helen Diller Family Comprehensive Cancer Center</s1>
<s2>San Francisco</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rui Tang" sort="Rui Tang" uniqKey="Rui Tang" last="Rui Tang">RUI TANG</name>
<affiliation><inist:fA14 i1="11"><s1>Amgen Inc.</s1>
<s2>Thousand Oaks</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Oliner, Kellys" sort="Oliner, Kellys" uniqKey="Oliner K" first="Kellys." last="Oliner">Kellys. Oliner</name>
<affiliation><inist:fA14 i1="11"><s1>Amgen Inc.</s1>
<s2>Thousand Oaks</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yizhoujiang" sort="Yizhoujiang" uniqKey="Yizhoujiang" last="Yizhoujiang">YIZHOUJIANG</name>
<affiliation><inist:fA14 i1="11"><s1>Amgen Inc.</s1>
<s2>Thousand Oaks</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Loh, Elwyn" sort="Loh, Elwyn" uniqKey="Loh E" first="Elwyn" last="Loh">Elwyn Loh</name>
<affiliation><inist:fA14 i1="12"><s1>Amgen Inc.</s1>
<s2>South San Francisco</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dubey, Sarita" sort="Dubey, Sarita" uniqKey="Dubey S" first="Sarita" last="Dubey">Sarita Dubey</name>
<affiliation><inist:fA14 i1="12"><s1>Amgen Inc.</s1>
<s2>South San Francisco</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gerritsen, Winald R" sort="Gerritsen, Winald R" uniqKey="Gerritsen W" first="Winald R." last="Gerritsen">Winald R. Gerritsen</name>
<affiliation><inist:fA14 i1="13"><s1>VU Medisch Centrum, Amsterdam/Radboud University Medical Center</s1>
<s2>Nijmegen</s2>
<s3>NLD</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0119238</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0119238 INIST</idno>
<idno type="RBID">Pascal:13-0119238</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B60</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone</title>
<author><name sortKey="Ryan, Charles J" sort="Ryan, Charles J" uniqKey="Ryan C" first="Charles J." last="Ryan">Charles J. Ryan</name>
<affiliation><inist:fA14 i1="01"><s1>University of California San Francisco Helen Diller Family Comprehensive Cancer Center</s1>
<s2>San Francisco</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rosenthal, Mark" sort="Rosenthal, Mark" uniqKey="Rosenthal M" first="Mark" last="Rosenthal">Mark Rosenthal</name>
<affiliation><inist:fA14 i1="02"><s1>The Royal Melbourne Hospital</s1>
<s2>Parkville</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ng, Siobhan" sort="Ng, Siobhan" uniqKey="Ng S" first="Siobhan" last="Ng">Siobhan Ng</name>
<affiliation><inist:fA14 i1="03"><s1>St. John of God Health Care</s1>
<s2>Subiaco</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alumkal, Joshi" sort="Alumkal, Joshi" uniqKey="Alumkal J" first="Joshi" last="Alumkal">Joshi Alumkal</name>
<affiliation><inist:fA14 i1="04"><s1>Oregon Health & Science University Knight Cancer Institute</s1>
<s2>Portland</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Picus, Joel" sort="Picus, Joel" uniqKey="Picus J" first="Joel" last="Picus">Joel Picus</name>
<affiliation><inist:fA14 i1="05"><s1>Washington University School of Medicine Site-man Cancer Center</s1>
<s2>St. Louis</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gravis, Gwenaelle" sort="Gravis, Gwenaelle" uniqKey="Gravis G" first="Gwenaëlle" last="Gravis">Gwenaëlle Gravis</name>
<affiliation><inist:fA14 i1="06"><s1>Institut Paoli Calmettes</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name>
<affiliation><inist:fA14 i1="07"><s1>Institut Gustave Roussy, University of Paris Sud</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Forget, Frederic" sort="Forget, Frederic" uniqKey="Forget F" first="Frédéric" last="Forget">Frédéric Forget</name>
<affiliation><inist:fA14 i1="08"><s1>Centre Hospitalier de l'Ardenne</s1>
<s2>Libramont</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Machiels, Jean Pascal" sort="Machiels, Jean Pascal" uniqKey="Machiels J" first="Jean-Pascal" last="Machiels">Jean-Pascal Machiels</name>
<affiliation><inist:fA14 i1="09"><s1>Université Catholique de Louvain, Cliniques Universitaires Saint-Luc</s1>
<s2>Bruxelles</s2>
<s3>BEL</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Srinivas, Sandy" sort="Srinivas, Sandy" uniqKey="Srinivas S" first="Sandy" last="Srinivas">Sandy Srinivas</name>
<affiliation><inist:fA14 i1="10"><s1>Stanford University</s1>
<s2>Palo Alto</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Min Zhu" sort="Min Zhu" uniqKey="Min Zhu" last="Min Zhu">MIN ZHU</name>
<affiliation><inist:fA14 i1="01"><s1>University of California San Francisco Helen Diller Family Comprehensive Cancer Center</s1>
<s2>San Francisco</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rui Tang" sort="Rui Tang" uniqKey="Rui Tang" last="Rui Tang">RUI TANG</name>
<affiliation><inist:fA14 i1="11"><s1>Amgen Inc.</s1>
<s2>Thousand Oaks</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Oliner, Kellys" sort="Oliner, Kellys" uniqKey="Oliner K" first="Kellys." last="Oliner">Kellys. Oliner</name>
<affiliation><inist:fA14 i1="11"><s1>Amgen Inc.</s1>
<s2>Thousand Oaks</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yizhoujiang" sort="Yizhoujiang" uniqKey="Yizhoujiang" last="Yizhoujiang">YIZHOUJIANG</name>
<affiliation><inist:fA14 i1="11"><s1>Amgen Inc.</s1>
<s2>Thousand Oaks</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Loh, Elwyn" sort="Loh, Elwyn" uniqKey="Loh E" first="Elwyn" last="Loh">Elwyn Loh</name>
<affiliation><inist:fA14 i1="12"><s1>Amgen Inc.</s1>
<s2>South San Francisco</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dubey, Sarita" sort="Dubey, Sarita" uniqKey="Dubey S" first="Sarita" last="Dubey">Sarita Dubey</name>
<affiliation><inist:fA14 i1="12"><s1>Amgen Inc.</s1>
<s2>South San Francisco</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gerritsen, Winald R" sort="Gerritsen, Winald R" uniqKey="Gerritsen W" first="Winald R." last="Gerritsen">Winald R. Gerritsen</name>
<affiliation><inist:fA14 i1="13"><s1>VU Medisch Centrum, Amsterdam/Radboud University Medical Center</s1>
<s2>Nijmegen</s2>
<s3>NLD</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Clinical cancer research</title>
<title level="j" type="abbreviated">Clin. cancer res.</title>
<idno type="ISSN">1078-0432</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical cancer research</title>
<title level="j" type="abbreviated">Clin. cancer res.</title>
<idno type="ISSN">1078-0432</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis</term>
<term>Antineoplastic agent</term>
<term>Biological marker</term>
<term>C-Onc gene</term>
<term>Castration</term>
<term>Human</term>
<term>Inhibition</term>
<term>Inhibitor</term>
<term>Mitoxantrone</term>
<term>Phase II trial</term>
<term>Prednisone</term>
<term>Prostate cancer</term>
<term>Protooncogene</term>
<term>Randomization</term>
<term>Resistance</term>
<term>Rilotumumab</term>
<term>Target</term>
<term>Targeting</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cible</term>
<term>Ciblage</term>
<term>Protooncogène</term>
<term>Gène onc cellulaire</term>
<term>Inhibiteur</term>
<term>Inhibition</term>
<term>Castration</term>
<term>Résistance</term>
<term>Cancer de la prostate</term>
<term>Randomisation</term>
<term>Homme</term>
<term>Essai clinique phase II</term>
<term>Traitement</term>
<term>Marqueur biologique</term>
<term>Analyse</term>
<term>Mitoxantrone</term>
<term>Prednisone</term>
<term>Anticancéreux</term>
<term>Rilotumumab</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose: To evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (IIGF)/scatter factor, combined with mitoxantrone and prednisone (MP) in patients with castration-resistant prostate cancer (CRPC). Experimental Design: This double-blinded phase II study randomized (1:1:1) patients with progressive, taxane-refractory CRPC to receive MP (12 mg/m<sup>2</sup>
 i.v. day 1, 5 mg twice a day orally days 1-21, respectively) plus 15 mg/kg rilotumumab, 7.5 mg/kg rilotumumab, or placebo (i.v. day 1) every 3 weeks. The primary endpoint was overall survival (OS). Results: One hundred and forty-four patients were randomized. Median OS was 12.2 versus 11.1 months [HR, 1.10; 80% confidence interval (CI), 0.82-1.48] in the combined rilotumumab versus control arms. Median progression-free survival was 3.0 versus 2.9 months (HR, 1.02; 80% CI, 0.79-1.31). Treatment appeared well tolerated with peripheral edema (24% vs. 8%) being more common with rilotumumab. A trend toward unfavorable OS was observed in patients with high tumor MET expression regardless of treatment. Soluble MET levels increased in all treatment arms. Total HGF levels increased in the rilotumumab arms. Rilotumumab showed linear pharmacokinetics when co-administered with MP. Conclusions: Rilotumumab plus MP had manageable toxicities and showed no efficacy improvements in this estimation study. High tumor MET expression may identify patients with CRPC with poorer prognosis.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1078-0432</s0>
</fA01>
<fA02 i1="01"><s0>CCREF4</s0>
</fA02>
<fA03 i2="1"><s0>Clin. cancer res.</s0>
</fA03>
<fA05><s2>19</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>RYAN (Charles J.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ROSENTHAL (Mark)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>NG (Siobhan)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>ALUMKAL (Joshi)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>PICUS (Joel)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GRAVIS (Gwenaëlle)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>FIZAZI (Karim)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>FORGET (Frédéric)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>MACHIELS (Jean-Pascal)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>SRINIVAS (Sandy)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>MIN ZHU</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>RUI TANG</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>OLINER (KellyS.)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>YIZHOUJIANG</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>LOH (Elwyn)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>DUBEY (Sarita)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>GERRITSEN (Winald R.)</s1>
</fA11>
<fA14 i1="01"><s1>University of California San Francisco Helen Diller Family Comprehensive Cancer Center</s1>
<s2>San Francisco</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>The Royal Melbourne Hospital</s1>
<s2>Parkville</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>St. John of God Health Care</s1>
<s2>Subiaco</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Oregon Health & Science University Knight Cancer Institute</s1>
<s2>Portland</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Washington University School of Medicine Site-man Cancer Center</s1>
<s2>St. Louis</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Institut Paoli Calmettes</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Institut Gustave Roussy, University of Paris Sud</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Centre Hospitalier de l'Ardenne</s1>
<s2>Libramont</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Université Catholique de Louvain, Cliniques Universitaires Saint-Luc</s1>
<s2>Bruxelles</s2>
<s3>BEL</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Stanford University</s1>
<s2>Palo Alto</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Amgen Inc.</s1>
<s2>Thousand Oaks</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Amgen Inc.</s1>
<s2>South San Francisco</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>VU Medisch Centrum, Amsterdam/Radboud University Medical Center</s1>
<s2>Nijmegen</s2>
<s3>NLD</s3>
<sZ>17 aut.</sZ>
</fA14>
<fA20><s1>215-224</s1>
</fA20>
<fA21><s1>2013</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>26073</s2>
<s5>354000502414060230</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2013 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>27 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>13-0119238</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Clinical cancer research</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Purpose: To evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (IIGF)/scatter factor, combined with mitoxantrone and prednisone (MP) in patients with castration-resistant prostate cancer (CRPC). Experimental Design: This double-blinded phase II study randomized (1:1:1) patients with progressive, taxane-refractory CRPC to receive MP (12 mg/m<sup>2</sup>
 i.v. day 1, 5 mg twice a day orally days 1-21, respectively) plus 15 mg/kg rilotumumab, 7.5 mg/kg rilotumumab, or placebo (i.v. day 1) every 3 weeks. The primary endpoint was overall survival (OS). Results: One hundred and forty-four patients were randomized. Median OS was 12.2 versus 11.1 months [HR, 1.10; 80% confidence interval (CI), 0.82-1.48] in the combined rilotumumab versus control arms. Median progression-free survival was 3.0 versus 2.9 months (HR, 1.02; 80% CI, 0.79-1.31). Treatment appeared well tolerated with peripheral edema (24% vs. 8%) being more common with rilotumumab. A trend toward unfavorable OS was observed in patients with high tumor MET expression regardless of treatment. Soluble MET levels increased in all treatment arms. Total HGF levels increased in the rilotumumab arms. Rilotumumab showed linear pharmacokinetics when co-administered with MP. Conclusions: Rilotumumab plus MP had manageable toxicities and showed no efficacy improvements in this estimation study. High tumor MET expression may identify patients with CRPC with poorer prognosis.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02R</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B14D02</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B20B02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Cible</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Target</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Blanco</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Ciblage</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Targeting</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Blancado</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Protooncogène</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Protooncogene</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Protooncogen</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Gène onc cellulaire</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>C-Onc gene</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Gen onc celular</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Inhibiteur</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Inhibitor</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Inhibidor</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Inhibition</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Inhibition</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Inhibición</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Castration</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Castration</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Castración</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Résistance</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Resistance</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Resistencia</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Cancer de la prostate</s0>
<s2>NM</s2>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Prostate cancer</s0>
<s2>NM</s2>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Cáncer de la próstata</s0>
<s2>NM</s2>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Randomisation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Randomization</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Aleatorización</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Homme</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Human</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Hombre</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Essai clinique phase II</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Phase II trial</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Ensayo clínico fase II</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Traitement</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Treatment</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>13</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Marqueur biologique</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Biological marker</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Marcador biológico</s0>
<s5>14</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Analyse</s0>
<s5>15</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Analysis</s0>
<s5>15</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Análisis</s0>
<s5>15</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Mitoxantrone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>16</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Mitoxantrone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>16</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Mitoxantrona</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>16</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Prednisone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>17</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Prednisone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>17</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Prednisona</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>17</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>23</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>23</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>23</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Rilotumumab</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>Rilotumumab</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="19" i2="X" l="SPA"><s0>Rilotumumab</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil génital mâle</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Male genital diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato genital macho patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'appareil urinaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Urinary system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Aparato urinario patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie de la prostate</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Prostate disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Prostata patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Anticorps monoclonal</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Monoclonal antibody</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Anticuerpo monoclonal</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Agent alkylant</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Alkylating agent</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Agente alquilante</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Dérivé de l'anthraquinone</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Anthraquinone derivatives</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Antraquinona derivado</s0>
<s5>43</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Antimétabolite</s0>
<s5>44</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Antimetabolic</s0>
<s5>44</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Antimetabólito</s0>
<s5>44</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Corticostéroïde</s0>
<s5>45</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Corticosteroid</s0>
<s5>45</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Corticoesteroide</s0>
<s5>45</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Hormone surrénalienne</s0>
<s5>46</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Adrenal hormone</s0>
<s5>46</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Hormona suprarrenal</s0>
<s5>46</s5>
</fC07>
<fN21><s1>091</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 13-0119238 INIST</NO>
<ET>Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone</ET>
<AU>RYAN (Charles J.); ROSENTHAL (Mark); NG (Siobhan); ALUMKAL (Joshi); PICUS (Joel); GRAVIS (Gwenaëlle); FIZAZI (Karim); FORGET (Frédéric); MACHIELS (Jean-Pascal); SRINIVAS (Sandy); MIN ZHU; RUI TANG; OLINER (KellyS.); YIZHOUJIANG; LOH (Elwyn); DUBEY (Sarita); GERRITSEN (Winald R.)</AU>
<AF>University of California San Francisco Helen Diller Family Comprehensive Cancer Center/San Francisco/Etats-Unis (1 aut., 11 aut.); The Royal Melbourne Hospital/Parkville/Australie (2 aut.); St. John of God Health Care/Subiaco/Australie (3 aut.); Oregon Health & Science University Knight Cancer Institute/Portland/Etats-Unis (4 aut.); Washington University School of Medicine Site-man Cancer Center/St. Louis/Etats-Unis (5 aut.); Institut Paoli Calmettes/Marseille/France (6 aut.); Institut Gustave Roussy, University of Paris Sud/Villejuif/France (7 aut.); Centre Hospitalier de l'Ardenne/Libramont/Belgique (8 aut.); Université Catholique de Louvain, Cliniques Universitaires Saint-Luc/Bruxelles/Belgique (9 aut.); Stanford University/Palo Alto/Etats-Unis (10 aut.); Amgen Inc./Thousand Oaks/Etats-Unis (12 aut., 13 aut., 14 aut.); Amgen Inc./South San Francisco/Etats-Unis (15 aut., 16 aut.); VU Medisch Centrum, Amsterdam/Radboud University Medical Center/Nijmegen/Pays-Bas (17 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Clinical cancer research; ISSN 1078-0432; Coden CCREF4; Etats-Unis; Da. 2013; Vol. 19; No. 1; Pp. 215-224; Bibl. 27 ref.</SO>
<LA>Anglais</LA>
<EA>Purpose: To evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (IIGF)/scatter factor, combined with mitoxantrone and prednisone (MP) in patients with castration-resistant prostate cancer (CRPC). Experimental Design: This double-blinded phase II study randomized (1:1:1) patients with progressive, taxane-refractory CRPC to receive MP (12 mg/m<sup>2</sup>
 i.v. day 1, 5 mg twice a day orally days 1-21, respectively) plus 15 mg/kg rilotumumab, 7.5 mg/kg rilotumumab, or placebo (i.v. day 1) every 3 weeks. The primary endpoint was overall survival (OS). Results: One hundred and forty-four patients were randomized. Median OS was 12.2 versus 11.1 months [HR, 1.10; 80% confidence interval (CI), 0.82-1.48] in the combined rilotumumab versus control arms. Median progression-free survival was 3.0 versus 2.9 months (HR, 1.02; 80% CI, 0.79-1.31). Treatment appeared well tolerated with peripheral edema (24% vs. 8%) being more common with rilotumumab. A trend toward unfavorable OS was observed in patients with high tumor MET expression regardless of treatment. Soluble MET levels increased in all treatment arms. Total HGF levels increased in the rilotumumab arms. Rilotumumab showed linear pharmacokinetics when co-administered with MP. Conclusions: Rilotumumab plus MP had manageable toxicities and showed no efficacy improvements in this estimation study. High tumor MET expression may identify patients with CRPC with poorer prognosis.</EA>
<CC>002B02R; 002B14D02; 002B20B02</CC>
<FD>Cible; Ciblage; Protooncogène; Gène onc cellulaire; Inhibiteur; Inhibition; Castration; Résistance; Cancer de la prostate; Randomisation; Homme; Essai clinique phase II; Traitement; Marqueur biologique; Analyse; Mitoxantrone; Prednisone; Anticancéreux; Rilotumumab</FD>
<FG>Pathologie de l'appareil génital mâle; Pathologie de l'appareil urinaire; Tumeur maligne; Cancer; Pathologie de la prostate; Anticorps monoclonal; Agent alkylant; Dérivé de l'anthraquinone; Antimétabolite; Corticostéroïde; Hormone surrénalienne</FG>
<ED>Target; Targeting; Protooncogene; C-Onc gene; Inhibitor; Inhibition; Castration; Resistance; Prostate cancer; Randomization; Human; Phase II trial; Treatment; Biological marker; Analysis; Mitoxantrone; Prednisone; Antineoplastic agent; Rilotumumab</ED>
<EG>Male genital diseases; Urinary system disease; Malignant tumor; Cancer; Prostate disease; Monoclonal antibody; Alkylating agent; Anthraquinone derivatives; Antimetabolic; Corticosteroid; Adrenal hormone</EG>
<SD>Blanco; Blancado; Protooncogen; Gen onc celular; Inhibidor; Inhibición; Castración; Resistencia; Cáncer de la próstata; Aleatorización; Hombre; Ensayo clínico fase II; Tratamiento; Marcador biológico; Análisis; Mitoxantrona; Prednisona; Anticanceroso; Rilotumumab</SD>
<LO>INIST-26073.354000502414060230</LO>
<ID>13-0119238</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B60 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000B60 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:13-0119238
   |texte=   Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri